Investor Relations

SEC Filings

SEC Filings

Document Highlights
Other Filings
Filing Description Filing Type Filing Date Event Date Download
8-K 8-K 5/19/2017 5/15/2017
Abstract: 8-K filed by Evolent Health (EVH) covering Entry into a Material Definitive Agreement and Financial Statements and Exhibits.
Prospectus 424B7 5/17/2017
Prospectus 424B7 5/16/2017
Prospectus FWP 5/15/2017
10-Q 10-Q 5/10/2017 3/31/2017
8-K 8-K 5/9/2017 5/9/2017
Abstract: 8-K filed by Evolent Health (EVH) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
8-K 8-K 5/1/2017 5/1/2017
Abstract: Registrant reported that on May 1, the sale of the shares of its class A common stock by the selling stockholders pursuant to the overallotment option closed. The opinion and the consent of Cravath, Swaine & Moore LLP were included by exhibit.
Proxy DEF 14A 4/27/2017 6/8/2017
Proxy DEFA14A 4/27/2017
8-K 8-K 3/31/2017 3/27/2017
Abstract: Registrant reported that on March 27, it entered into an underwriting agreement for the sale of 7.5 million of its class A common stock. The underwriting agreement, and the opinion and the consent of Cravath Swaine & Moore LLP were included by exhibit.
Prospectus 424B7 3/29/2017
8-K 8-K 3/27/2017 3/27/2017
Abstract: Registrant filed the unaudited pro forma condensed combined statement of operations of the registrant and Valence Health Inc., excluding Cicerone Health Solutions Inc., for the year ended Dec. 31, 2016.
Prospectus 424B7 3/27/2017
Prospectus 424B3 3/27/2017
10-K 10-K 3/3/2017 12/31/2016
8-K 8-K 2/28/2017 2/28/2017
Abstract: On Feb. 28, registrant reported its financial results for the quarter and for the year ended Dec. 31, 2016.
8-K 8-K 2/8/2017 2/8/2017
Abstract: On Feb. 8, registrant reported the schedule of its 2017 annual meeting of shareholders.
Annual Report AR 12/31/2016
8-K 8-K/A 12/19/2016 12/19/2016
Abstract: Registrant filed an amendment to the Form 8-K filed Oct. 3 to filed exhibit 23.1.
8-K 8-K 12/5/2016 12/5/2016
Abstract: Registrant reported that on Nov. 29, it and Evolent Health LLC entered into a purchase agreement JP Morgan Securities LLC and Goldman Sachs & Co. issue and sell $110.0 million aggregate principal amount of its 2.00% convertible senior notes due 2021. The indenture, among other things, was included by exhibit.

Displaying 1 to 20 (of 66 filings)
  • 1